Shopping Cart
- Remove All
- Your shopping cart is currently empty
NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative activity and inhibits the proliferation of BTKC481S mutant TMD8 cells.NX-2127 potently catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) at 25 nM and 54 nM, respectively. NX-2127 is associated with the immune system, stimulating T cell activation and increasing IL-2 production in primary human T cells.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $105 | In Stock | |
5 mg | $259 | In Stock | |
10 mg | $389 | In Stock | |
25 mg | $713 | In Stock | |
50 mg | $987 | In Stock | |
100 mg | $1,360 | In Stock | |
200 mg | $1,830 | In Stock |
Description | NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative activity and inhibits the proliferation of BTKC481S mutant TMD8 cells.NX-2127 potently catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) at 25 nM and 54 nM, respectively. NX-2127 is associated with the immune system, stimulating T cell activation and increasing IL-2 production in primary human T cells. |
Synonyms | NX2127, NX 2127 |
Molecular Weight | 719.83 |
Formula | C39H45N9O5 |
Cas No. | 2416131-46-7 |
Smiles | O=C1C=2C(C(=O)N1C3C(=O)NC(=O)CC3)=CC=C(C2)N4C[C@H](CN5CCC(CC5)C6=CC=C(NC=7C(C(N)=O)=NC=C(N7)N8CCCCC8)C=C6)CC4 |
Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 150 mg/mL (208.38 mM), Sonication is recommended. ![]() | |||||||||||||||||||||||||||||||||||
In Vivo Formulation | 2% DMSO+40% PEG300+5% Tween 80+53% Saline: 3 mg/mL (4.17 mM), Suspension. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.![]() | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.